Logo image of OTIC

OTONOMY INC (OTIC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OTIC - US68906L1052 - Common Stock

0.077 USD
-0.01 (-11.19%)
Last: 12/22/2022, 8:00:02 PM
0.083 USD
+0.01 (+7.79%)
After Hours: 12/22/2022, 8:00:02 PM
Fundamental Rating

1

OTIC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. OTIC has a bad profitability rating. Also its financial health evaluation is rather negative. OTIC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • OTIC had negative earnings in the past year.
  • In the past year OTIC has reported a negative cash flow from operations.
OTIC Yearly Net Income VS EBIT VS OCF VS FCFOTIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

  • The profitability ratios for OTIC are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTIC Yearly ROA, ROE, ROICOTIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for OTIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTIC Yearly Profit, Operating, Gross MarginsOTIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -10K -20K -30K -40K

2

2. Health

2.1 Basic Checks

  • OTIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for OTIC has been increased compared to 1 year ago.
  • The debt/assets ratio for OTIC is higher compared to a year ago.
OTIC Yearly Shares OutstandingOTIC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
OTIC Yearly Total Debt VS Total AssetsOTIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -16.93, we must say that OTIC is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -16.93, OTIC is doing worse than 90.99% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that OTIC is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.01, OTIC is in line with its industry, outperforming 49.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -16.93
ROIC/WACCN/A
WACC10.41%
OTIC Yearly LT Debt VS Equity VS FCFOTIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.74 indicates that OTIC should not have too much problems paying its short term obligations.
  • OTIC has a worse Current ratio (1.74) than 75.23% of its industry peers.
  • A Quick Ratio of 1.74 indicates that OTIC should not have too much problems paying its short term obligations.
  • OTIC's Quick ratio of 1.74 is on the low side compared to the rest of the industry. OTIC is outperformed by 69.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
OTIC Yearly Current Assets VS Current LiabilitesOTIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

1

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.94% over the past year.
  • The Revenue for OTIC has decreased by -100.00% in the past year. This is quite bad
  • The Revenue for OTIC have been decreasing by -28.73% on average. This is quite bad
EPS 1Y (TTM)4.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-44.97%
Revenue growth 5Y-28.73%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 2.08% on average over the next years.
  • OTIC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y3.04%
EPS Next 2Y10.42%
EPS Next 3Y-0.66%
EPS Next 5Y2.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OTIC Yearly Revenue VS EstimatesOTIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 500K 1M
OTIC Yearly EPS VS EstimatesOTIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OTIC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OTIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTIC Price Earnings VS Forward Price EarningsOTIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTIC Per share dataOTIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.42%
EPS Next 3Y-0.66%

0

5. Dividend

5.1 Amount

  • OTIC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

OTONOMY INC

NASDAQ:OTIC (12/22/2022, 8:00:02 PM)

After market: 0.083 +0.01 (+7.79%)

0.077

-0.01 (-11.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)02-27
Inst Owners0%
Inst Owner Change0%
Ins Owners10.54%
Ins Owner Change0%
Market Cap4.40M
Revenue(TTM)N/A
Net Income(TTM)-52.26M
Analysts77.78
Price Target9.18 (11822.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.99%
Min EPS beat(2)6.86%
Max EPS beat(2)7.12%
EPS beat(4)3
Avg EPS beat(4)2.53%
Min EPS beat(4)-7.44%
Max EPS beat(4)7.12%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.52%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0
BVpS0.37
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z -16.93
F-Score2
WACC10.41%
ROIC/WACCN/A
Cap/Depr(3y)35.87%
Cap/Depr(5y)49.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
EPS Next Y3.04%
EPS Next 2Y10.42%
EPS Next 3Y-0.66%
EPS Next 5Y2.08%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-44.97%
Revenue growth 5Y-28.73%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-8.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.44%
OCF growth 3YN/A
OCF growth 5YN/A

OTONOMY INC / OTIC FAQ

What is the fundamental rating for OTIC stock?

ChartMill assigns a fundamental rating of 1 / 10 to OTIC.


Can you provide the valuation status for OTONOMY INC?

ChartMill assigns a valuation rating of 3 / 10 to OTONOMY INC (OTIC). This can be considered as Overvalued.


What is the profitability of OTIC stock?

OTONOMY INC (OTIC) has a profitability rating of 0 / 10.


How financially healthy is OTONOMY INC?

The financial health rating of OTONOMY INC (OTIC) is 1 / 10.